Asymmetry Capital Management
Latest statistics and disclosures from Asymmetry Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMRN, Horizon Therapeutics, UNH, ABBV, IQV, and represent 36.79% of Asymmetry Capital Management's stock portfolio.
- Added to shares of these 10 stocks: BMRN (+$16M), UNH (+$14M), ABBV (+$13M), IQV (+$13M), CNC (+$12M), Horizon Therapeutics (+$12M), JNJ (+$9.5M), NTRA (+$9.5M), ARGX (+$7.3M), APLS (+$6.6M).
- Started 9 new stock positions in UNH, JNJ, ARGX, APLS, NTRA, CNC, IQV, BMRN, ABBV.
- Reduced shares in these 10 stocks: , MDT (-$11M), , HOLX (-$10M), SAGE (-$10M), Arena Pharmaceuticals (-$8.9M), PTCT (-$8.0M), AZN (-$7.0M), KYMR (-$5.2M), BAX.
- Sold out of its positions in Arena Pharmaceuticals, AZN, Avalo Therapeutics, RNA, BAX, Gemini Therapeutics, HOLX, PODD, KYMR, LRMR. PTCT, SAGE, ALKS, MDT.
- Asymmetry Capital Management was a net buyer of stock by $23M.
- Asymmetry Capital Management has $188M in assets under management (AUM), dropping by 13.24%.
- Central Index Key (CIK): 0001657134
Tip: Access up to 7 years of quarterly data
Positions held by Asymmetry Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Asymmetry Capital Management
Asymmetry Capital Management holds 24 positions in its portfolio as reported in the December 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical (BMRN) | 8.3 | $16M | NEW | 178k | 88.35 |
|
| Horizon Therapeutics | 7.9 | $15M | +451% | 138k | 107.76 |
|
| UnitedHealth (UNH) | 7.2 | $14M | NEW | 27k | 502.12 |
|
| Abbvie (ABBV) | 6.8 | $13M | NEW | 94k | 135.40 |
|
| Iqvia Holdings (IQV) | 6.6 | $13M | NEW | 44k | 282.15 |
|
| Centene Corporation (CNC) | 6.5 | $12M | NEW | 148k | 82.40 |
|
| Bellus Health | 5.5 | $10M | +19% | 1.3M | 8.05 |
|
| Cytokinetics (CYTK) | 5.4 | $10M | -8% | 225k | 45.58 |
|
| Johnson & Johnson (JNJ) | 5.1 | $9.5M | NEW | 56k | 171.07 |
|
| Natera (NTRA) | 5.0 | $9.5M | NEW | 102k | 93.39 |
|
| Amicus Therapeutics (FOLD) | 4.4 | $8.3M | +9% | 717k | 11.55 |
|
| Argenx Se - Adr (ARGX) | 3.9 | $7.3M | NEW | 21k | 350.17 |
|
| Kura Oncology (KURA) | 3.7 | $7.0M | +158% | 502k | 14.00 |
|
| Apellis Pharmaceuticals (APLS) | 3.5 | $6.6M | NEW | 139k | 47.28 |
|
| Mirati Therapeutics | 3.4 | $6.4M | +4% | 44k | 146.69 |
|
| Iveric Bio | 3.3 | $6.3M | +5% | 376k | 16.72 |
|
| Quanterix Ord (QTRX) | 3.2 | $6.1M | -11% | 143k | 42.40 |
|
| Iteos Therapeutics | 2.6 | $4.9M | +82% | 105k | 46.56 |
|
| Dice Therapeutics | 2.5 | $4.7M | -32% | 185k | 25.31 |
|
| Avadel Pharmaceuticals Adr | 1.6 | $3.0M | -22% | 369k | 8.08 |
|
| Aclaris Therapeutics (ACRS) | 1.5 | $2.9M | -17% | 199k | 14.54 |
|
| Pmv Pharmaceuticals (PMVP) | 1.2 | $2.3M | -3% | 98k | 23.10 |
|
| Regulus Therapeutics | 0.5 | $860k | +94% | 2.7M | 0.31 |
|
| Bcls Acquisition Corp | 0.4 | $699k | -2% | 71k | 9.79 |
|
Past Filings by Asymmetry Capital Management
SEC 13F filings are viewable for Asymmetry Capital Management going back to 2015
- Asymmetry Capital Management 2021 Q4 filed Jan. 19, 2022
- Asymmetry Capital Management 2021 Q3 filed Nov. 4, 2021
- Asymmetry Capital Management 2021 Q2 filed July 28, 2021
- Asymmetry Capital Management 2021 Q1 filed May 11, 2021
- Asymmetry Capital Management 2020 Q4 filed Feb. 11, 2021
- Asymmetry Capital Management 2020 Q3 filed Nov. 12, 2020
- Asymmetry Capital Management 2020 Q2 filed Aug. 6, 2020
- Asymmetry Capital Management 2020 Q1 filed May 13, 2020
- Asymmetry Capital Management 2019 Q4 filed Feb. 12, 2020
- Asymmetry Capital Management 2019 Q3 filed Nov. 12, 2019
- Asymmetry Capital Management 2019 Q2 filed Aug. 7, 2019
- Asymmetry Capital Management 2019 Q1 filed May 8, 2019
- Asymmetry Capital Management 2018 Q4 filed Feb. 12, 2019
- Asymmetry Capital Management 2018 Q3 filed Nov. 8, 2018
- Asymmetry Capital Management 2018 Q2 filed Aug. 7, 2018
- Asymmetry Capital Management 2018 Q1 filed May 9, 2018